M
Mnemo Therapeutics
Developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. EnfiniT platform, a groundbreaking drug discovery engine
About Mnemo Therapeutics
MNEMO specializes in providing robust data protection solutions that ensure compliance with global privacy regulations, including the General Data Protection Regulation (GDPR) and the French Data Protection Act. The company serves a diverse range of clients, including businesses and organizations that handle sensitive personal data and require stringent data security measures. Operating primarily in the data protection and cybersecurity market, MNEMO's business model focuses on offering tailored solutions that safeguard personal data against breaches and unauthorized access. The company generates revenue through subscription-based services, consulting fees, and implementation of data protection frameworks. MNEMO's services are designed to meet the specific needs of clients, ensuring that their data management practices align with legal requirements and industry standards. The company also leverages advanced analytics tools, such as Google Analytics, to enhance its service offerings and provide clients with actionable insights. Additionally, MNEMO maintains a global presence with affiliates in New York, ensuring that it can support clients with international data transfer needs while adhering to applicable regulations.
Source: Dealroom company dataAt a glance
- Status
- Low Activity
- Founded
- 2019
- Headquarters
- Paris, France
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Spinout, Biotech and Pharma, AI Drug Discovery, biotech medtech and e-health, Observatoire Deeptech, Techbio
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2021 | $83M | $330M | Casdin Capital · Redmile Group · Alexandria Venture Investments · Emerson Collective | ↗ |
| SEEDOther financing | Dec 2020 | $0 | — | Casdin Capital | — |
Growth signals
Latest recorded traffic for Mnemo Therapeutics is 240 monthly website visits, down 68.8% over the last three months. Mnemo Therapeutics's team declined 35.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A4 investors entered at this stage
Sofinnova Partners
Redmile Group
Alexandria Venture Investments
Emerson Collective
Other known investors2 additional known investors
Institut Curie
PSL University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mnemo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mnemo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.